Glucose controlGiven the high incidence of type 2 in the US I would say this is interesting. I did not know that statins normally present increased risk to diabetics, where it appears CaPre actually can be beneficial.
Topline results will include readout of the primary endpoint, which is CaPre’s overall impact on lowering triglycerides. In addition, the topline results will include CaPre’s impact on LDL and HDL cholesterol, non-HDL cholesterol, and HbA1c, which is an important biomarker of glucose control in diabetic patients.
Pierre Lemieux added, “Previous studies with CaPre have shown its potential to improve glucose metabolism. We expect that a significant number of the patients enrolled in the TRILOGY studies will have diabetes with baseline HbA1c levels above 6.5. Therefore, there should be adequate patient numbers and data to evaluate statistical evidence, if there is a clinically meaningful effect from CaPre on HbA1C and/or other biomarkers of long-term glucose intolerance. Since there is an increased risk from the use of statins in diabetic patients with cardiovascular risk factors, and given the fact hypertriglyceridemia is a major risk factor for type 2 diabetes, beneficial effects of CaPre on glycemic parameters could be advantageous and an important differentiator versus other marketed omega-3 therapeutic drugs